Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R A Fleming

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
The American Surgeon|July 11, 2000
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal originB W Loggie, R A Fleming, R P McQuellon, et al.
Arthritis and Rheumatism|December 1, 1991
Aspirin alters methotrexate disposition in rheumatoid arthritis patientsC F Stewart, R A Fleming, B F Germain, et al.
Cancer Research|May 15, 1992
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patientsR A Fleming, G Milano, A Thyss, et al.
Bulletin Du Cancer|January 1, 1992
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance]M C Etienne, G Milano, R A Fleming, et al.
Journal of Surgical Oncology|September 18, 1997
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgeryM Y Chen, C Chiles, B W Loggie, et al.
British Journal of Cancer|October 1, 1992
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusionR A Fleming, G A Milano, M C Etienne, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 10, 2001
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosisR P McQuellon, B W Loggie, R A Fleming, et al.
The American Surgeon|October 18, 2001
Prospective trial for the treatment of malignant peritoneal mesotheliomaB W Loggie, R A Fleming, R P McQuellon, et al.
Bone Marrow Transplantation|April 1, 1996
Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesnaR A Fleming, J M Cruz, C D Webb, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Disposition of total and unbound etoposide following high-dose therapyT L Schwinghammer, R A Fleming, C S Rosenfeld, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
The American Surgeon|July 11, 2000
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal originB W Loggie, R A Fleming, R P McQuellon, et al.
Arthritis and Rheumatism|December 1, 1991
Aspirin alters methotrexate disposition in rheumatoid arthritis patientsC F Stewart, R A Fleming, B F Germain, et al.
Cancer Research|May 15, 1992
Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patientsR A Fleming, G Milano, A Thyss, et al.
Bulletin Du Cancer|January 1, 1992
[Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance]M C Etienne, G Milano, R A Fleming, et al.
Journal of Surgical Oncology|September 18, 1997
Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgeryM Y Chen, C Chiles, B W Loggie, et al.
British Journal of Cancer|October 1, 1992
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusionR A Fleming, G A Milano, M C Etienne, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 10, 2001
Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosisR P McQuellon, B W Loggie, R A Fleming, et al.
The American Surgeon|October 18, 2001
Prospective trial for the treatment of malignant peritoneal mesotheliomaB W Loggie, R A Fleming, R P McQuellon, et al.
Bone Marrow Transplantation|April 1, 1996
Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesnaR A Fleming, J M Cruz, C D Webb, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Disposition of total and unbound etoposide following high-dose therapyT L Schwinghammer, R A Fleming, C S Rosenfeld, et al.
Pageof 7